The 5-nitrofuran-2-ylmethylidene group as a potential bioreductively activated prodrug system for diol-containing drugs

Anti-Cancer Drug Design

Volumn 13, Issue 6, 1998, Pages 655-662

  Mahmud, Nazia R ^a   Garrett, Shane W ^a   Threadgill, Michael D ^a  

^a University of Bath   (United Kingdom)

Author keywords

Biomimetic cleavage; Bioreductive prodrugs; Nitrofuran

Indexed keywords

2,2 DIMETHYL 1 PHENYLPROPANE 1,3 DIOL; 5 NITROFURAN 2 CARBOXALDEHYDE; 5 NITROFURAN 2 YLMETHYLIDENE DERIVATIVE; ACETAL DERIVATIVE; ALDEHYDE DERIVATIVE; BENZENE; NITROFURAN DERIVATIVE; PALLADIUM; PRODRUG; SODIUM BOROHYDRIDE; STYRENE GLYCOL; UNCLASSIFIED DRUG;

ARTICLE; POLYMERIZATION; PRIORITY JOURNAL; REDUCTION;

ACETALS; ANTINEOPLASTIC AGENTS; BENZENE; BOROHYDRIDES; CELL HYPOXIA; CYCLIZATION; DIOXANES; DIOXOLANES; ETHYLENE GLYCOLS; HEAT; HYDROGEN-ION CONCENTRATION; NITROFURANS; OXIDATION-REDUCTION; PALLADIUM; PRODRUGS;

EID: 0031716267     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BERRY, J.M., WATSON, C.Y., WHISH, W J.D. & THREADGILL, M.D. (1997). 5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated prodrug system. Journal of the Chemical Society, Perkin Transactions 1, 1147.
2. BRITISH PATENT (1963). Cyclic acetals derived from 5-nitro-2-furaldehyde. No. 933681.
3. DENNY, W.A., WILSON, W.R. &. HAY M.P. (1996). Recent developments in the design of bioreductive drugs. British Journal of Cancer, 74, S32.
4. JENKINS, T.C., NAYLOR, M.A., O'NEILL, P., THREADGILL, M D , COLE, S., STRATFORD, I.J., ADAMS, G.E., FIELDEN, E.M., SUTO, M J. & STEIR, M.J. (1990). Synthesis and evaluation of 1-[3-(2-haloethylamino)propyl]-2-nitroimidazoles as pro-drugs of RSU 1069 and its analogues which are radiosensitizers and bioreductively-activated cytotoxins. Journal of Medicinal Chemistry, 33, 2603.
5. KENNEDY, K.A , TEICHER, B.A., ROCKWELL, S. & SARTORELLI, A.C. (1980). The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochemical Pharmacology, 29, 1.
6. KEYES, S R , ROCKWELL, S. & SARTORELLI, A.C. (1985). Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Research, 45, 3642.
7. 19F magnetic resonance spectroscopy in vivo. International Journal of Radiation Oncology, Biology and Physics, 16, 925.
8. NAYLOR, M.A., STEPHENS, M.A , COLE, S, THREADGILL, M.D., STRATFORD, I.J., O'NEILL, P., FIELDEN, E.M. & ADAMS, G.E. (1990). Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively-activated cytotoxins. Journal of Medicinal Chemistry, 33, 2508.
9. OKUNIEFF, P., HOECKEL, M., DUNPHY, E.P., SCHLENGER, K., KNOOP, C. & VAUPEL, P. (1993). Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone. International Journal of Radiation Oncology Biology and Physics, 26, 631.
10. 123I-iodoazomycin arabinoside - preliminary report of a clinical study. British Journal of Cancer, 65, 90.
11. REIK, R. (1897). Über das aus Isobutyraldehyd und Benzaldehyd entstehende Glykol und sein Verhalten gegen Schwefelsäure. Monatshefte für Chemie, 18, 598.
12. SINHABABU, A K. & THAKKER, D R (1996). Prodrugs of anticancer agents. Advanced Drug Delivery Reviews, 19, 241.
13. SWENSON, D.H., LASTER, B.H. & METZGER, R.L. (1996). Synthesis and evaluation of a boronated nitroimidazole for boron neutron capture therapy. Journal of Medicinal Chemistry, 39, 1540.
14. TERCEL, M., WILSON W.R., ANDERSON R F. & DENNY, W.A. (1996) Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Journal of Medicinal Chemistry, 39, 1084.
15. VAUPEL, P., KALLINOWSKI, F. & OKUNIEFF, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours - a review. Cancer Research, 49, 6449.
16. WEBER, G , PRAJDA, N , ABONYI, M., LOOK, K.Y & TRICOT, G. (1996). Tiazofurin: molecular and clinical action. Anticancer Research, 16, 3313.
17. 11B magnetic resonance spectroscopy. International Journal of Radiation Biology, 70, 587.
18. WORKMAN, P. & STRATFORD, I.J (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer and Metastasis Reviews, 12, 73.